Bayer Thrombosis drug Asundexian shows positive study result
Asundexian is a so-called factor 11a inhibitor and was being compared to a drug sold under the brand name Eliquis by Pfizer and Bristol-Myers Squibb Co.
New Delhi: Bayer AG said a new thrombosis prevention drug showed positive results in a clinical study designed to determine its safety and optimal dosing.
The company's investigational treatment asundexian demonstrated a 67% reduction in ISTH major and clinically relevant non-major bleeding in patients with atrial fibrillation at risk of stroke, Bayer said Sunday.
Asundexian is a so-called factor 11a inhibitor and was being compared to a drug sold under the brand name Eliquis by Pfizer Inc. and Bristol-Myers Squibb Co.
Bayer is seeking to turn asundexian into a new treatment option in thrombosis prevention to help reignite growth in the pharma business as its blockbusters -- the eye-care treatment Eylea and the blood-thinner Xarelto -- approach the end of their patent protection periods. Bayer is trying to offset the expected sales slowdown by pivoting to cutting-edge medicines.
Bayer shares hit a 52-week high at 65.10 euros on Monday, a 3.3% increase from the previous close.
Chief Executive Officer Werner Baumann has faced investor discontent since the controversial decision to buy Monsanto for $63 billion, which brought U.S. litigation claiming the company's weedkiller Roundup causes cancer. Bayer denies the link but has pledged to spend as much as $16 billion to try to move on. Still, long-time investor Temasek Holdings Pte is pushing for Baumann's ouster, Bloomberg has reported.
The trial of asundexian was designed as a "dose-finding phase 2" study and "not powered to discern or test differences in the rates of thrombotic events," Bayer said in a statement.
Ruchika joined Medical Dialogue as an Desk Editor for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at email@example.com Contact no. 011-43720751